FDA Accepts New Drug Application for Revefenacin in Treatment of COPD
The U.S. Food and Drug Administration (FDA) accepted for review a New Drug Application (NDA) submitted by Theravance Biopharma and Mylan for their collaborative compound revefenacin (TD-4208), a bronchodilator for the treatment of chronic obstructive pulmonary disease (COPD) in adults. The two pharmaceutical companies are aiming to develop and…